NDA 021654 · Waylis Therap
Lovaza
Omega-3-Acid Ethyl Esters · Oral
NovelLast checked: Nov 20, 2026Latest source record: Sep 4, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Nov 10, 2004
Approved uses
2
Original approval plus efficacy supplements
Registered trials
96
30 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 16, 2009 Supplement 22 · Efficacy LetterLabel
- Nov 10, 2004 Original approval · Type 1 - New Molecular Entity NovelReviewLabelLetter
1 products under this application
- LOVAZA · OMEGA-3-ACID ETHYL ESTERS 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Omega-3 Ethyl Esters" as an intervention, any sponsor and status, largest first.
- ASCEND: A Study of Cardiovascular Events iN DiabetesPivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT00135226 · 15,480 participants · Start Mar 2005 · Primary completion Mar 12, 2018
Drug: Aspirin; Omega-3 Ethyl Esters and 2 more · For: Diabetes Mellitus
Sites: Oxford, United Kingdom
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00069784 · 12,537 participants · Start Aug 2003 · Primary completion Dec 2011
Drug: insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA) and 1 more · For: Diabetes Mellitus, Non-Insulin-Dependent
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Cove, Australia · 40 sites in all
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on StatinPivotal-lookingCompleted
Amarin Pharma Inc.Industry
NCT01492361 · 8,179 participants · Start Nov 2011 · Primary completion May 2018
Drug: AMR101; Placebo and 1 more · For: Cardiovascular Diseases
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 410 sites in all
- OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial InfarctionPivotal-lookingCompleted
Stiftung Institut fuer HerzinfarktforschungAcademic, hospital or other
NCT00251134 · 3,800 participants · Start Oct 2003 · Primary completion Jun 2008
Drug: Zodin (drug); Olive oil (placebo) · For: Myocardial Infarction
Sites: Ludwigshafen am Rhein, Germany; Duisburg, Germany; Essen, Germany · 10 sites in all
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)Pivotal-lookingCompleted
Amarin Pharma Inc.Industry
NCT01047501 · 702 participants · Start Dec 2009 · Primary completion Feb 2011
Drug: AMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day and 1 more · For: Hypertriglyceridemia
Sites: Muscle Shoals, Alabama; Scottsboro, Alabama; Phoenix, Arizona · 80 sites in all
- Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial FibrillationPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00402363 · 663 participants · Start Nov 2006 · Primary completion Jan 2010
Drug: omega-3-acid ethyl esters; Placebo · For: Fibrillation, Atrial
Sites: Birmingham, Alabama; Huntsville, Alabama; Anchorage, Alaska · 178 sites in all
- Efficacy of TAK-085 in Participants With HypertriglyceridemiaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT01350973 · 611 participants · Start Nov 2009 · Primary completion Dec 2010
Drug: Omega-3-acid ethyl esters 90 (TAK-085); Eicosapentaenoic acid-ethyl (EPA-E) · For: Hypertriglyceridemia
- Efficacy of MND-2119 in Participants With HypertriglyceridemiaPivotal-lookingCompleted
Mochida Pharmaceutical Company, Ltd.Industry
NCT03693131 · 580 participants · Start Oct 27, 2018 · Primary completion Jun 15, 2019
Drug: Icosapent (MND-2119); Icosapent (EPADEL CAPSULES 300) · For: Hypertriglyceridemia
Sites: Tokyo, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lovaza (Omega-3 Acid Ethyl Esters)
2024 spending
$7.1M
Beneficiaries
1,364
4,393 claims
Per beneficiary
$5,172
$7.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $2,289,308 |
| 2022 | $5,939,892 |
| 2023 | $6,971,224 |
| 2024 | $7,055,049 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study.
Pratt CM, Reiffel JA, Ellenbogen KA, et al. · Am Heart J 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson MH, Johnson J, Rooney MW, et al. · J Clin Lipidol 2012 · Comparative Study, Randomized Controlled Trial
- A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid TechnologiesTM (ALT®) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza®.
Lopez-Toledano MA, Thorsteinsson T, Daak A, et al. · Clin Ther 2017 · Clinical Trial, Phase I, Comparative Study
- Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH, Stein EA, Bays HE, et al. · Clin Ther 2007 · Multicenter Study, Randomized Controlled Trial
- Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial.
Sandhu N, Schetter SE, Liao J, et al. · Cancer Prev Res (Phila) 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome.
Borja MS, Hammerson B, Tang C, et al. · PLoS One 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Waylis Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.